The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
A. Folkes, K. Ahmadi, W. Alderton, Sonia Alix +30 more
2008Journal of Medicinal Chemistry767 citations Open access
Semantic Scholar

